You are here: Industry Insights > Akebia

News List

Akebia Announces Otsuka's Submission of Initial Marketing Authorization Application to the European Medicines Agency for Vadadustat for the Treatment of Patients with Anemia due to Chronic Kidney Dise prnewswire
November 01, 2021
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, and its collaborator, Otsuka Pharmaceutical Co., Ltd. (Otsuka)...
Akebia and Otsuka Announce FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis drugs
June 21, 2021
Akebia today announced that the U.S. Food and Drug Administration accepted for filing the New Drug Application for vadadustat for the treatment of anemia due to chronic kidney disease in both adult patients on dialysis and adult patients not on dialysis.
Akebia Announces Top-Line Results from Vadadustat Study americanpharmaceuticalreview
September 07, 2020
Akebia Therapeutics announces top-line results from PRO2TECT, the second of its two global Phase 3 cardiovascular outcomes programs.
Akebia Begins Investigator-Sponsored Vadadustat Study for ARDS in COVID-19 americanpharmaceuticalreview
July 23, 2020
Akebia Therapeutics announced the initiation of an investigator-sponsored study evaluating the use of vadadustat, Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a potential therapy to prevent and ...
Akebia submits New Drug Application for Anemia drug in Japan biospectrumasia
July 23, 2019
The JNDA is the first regulatory submission for marketing approval of vadadustat and, if approved, is expected to lead to the first launch of vadadustat worldwide.
Akebia Therapeutics Sends Letter to Shareholders firstwordpharma
November 14, 2018
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (Nasdaq: AKBA) mailed a letter to Akebia shareholders in connection with the special meeting
Akebia Announces $85M Public Offering biospace
March 26, 2018
Cambridge, Massachusetts-based Akebia Therapeutics announced plans to offer and sell about $85 million of its common stock in an underwritten public offering.
Akebia Therapeutics Names CMO contractpharma
May 26, 2017
Rita Jain, M.D. has been appointed senior vice president and chief medical officer, Akebia Therapeutics, Inc. Dr. Jain will be responsible for leading the clinical development of the company’s HIF pipeline...